BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, May 26, 2024
See today's BioWorld
Home
» 12-year-old comments shape FDA guidance on NSCLC endpoints
To read the full story,
subscribe
or
sign in
.
12-year-old comments shape FDA guidance on NSCLC endpoints
April 22, 2015
By
Mari Serebrov
No Comments
Reflecting its "current thinking," the FDA released final guidance Tuesday on efficacy endpoints for clinical trials of non-small-cell lung cancer (NSCLC) drugs.
BioWorld